Ki-67 is a predictor of acromegaly control with octreotide LAR independent of SSTR2 status and relates to cytokeratin pattern

European Journal of Endocrinology

Volumn 169, Issue 2, 2013, Pages 217-223

  Kasuki, Leandro ^a,b   Wildemberg, Luiz Eduardo Armondi ^a   Neto, Leonardo Vieira ^a,c   Marcondes, Jorge ^a   Takiya, Christina M ^a   Gadelha, Monica R ^a,d  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b Bonsucesso Federal Hospital   (Brazil)

^c Lagoa Federal Hospital   (Brazil)

^d Rodolpho Paulo Rocco   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKERATIN; KI 67 ANTIGEN; OCTREOTIDE; SOMATOSTATIN RECEPTOR 2;

ACROMEGALY; ADULT; ARTICLE; CELL LABELING; CELL NUCLEUS; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE CONTROL; DRUG RESPONSE; FEMALE; GROWTH HORMONE SECRETING ADENOMA; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ACROMEGALY; ADULT; ANTINEOPLASTIC AGENTS, HORMONAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KERATINS; KI-67 ANTIGEN; LOGISTIC MODELS; MIDDLE AGED; MULTIVARIATE ANALYSIS; OCTREOTIDE; PITUITARY NEOPLASMS; RECEPTORS, SOMATOSTATIN; YOUNG ADULT;

EID: 84880952646     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-13-0349     Document Type: Article

References (35)

1. Colao A, Ferone D, Marzullo P & Lombardi G. Systemic complications of acromegaly: Epidemiology, pathogenesis, and management. Endocrine Journal 2004 25 102-152. (doi:10.1210/ er.2002-0022)
2. Melmed S, Colao A, Barkan A, Molitch M, Grossman AB, Kleinberg D, Clemmons D, Chanson P, Laws E, Schlechte J et al. Guidelines for acromegaly management: An update. Journal of Clinical Endocrinology and Metabolism 2009 94 1509-1517. (doi:10.1210/jc.2008-2421)
3. Nomikos P, Buchfelder M & Fahlbusch R. The outcome of surgery in 668 patients with acromegaly using current criteria of biochemical 'cure'. European Journal of Endocrinology 2005 152 379-387. (doi:10.1530/eje.1.01863)
4. Mercado M, Borges F, Bouterfa H, Chang TC, Chervin A, Farrall AJ, Patocs A, Petersenn S, Podoba J, Safari M et al. A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly. Clinical Endocrinology 2007 66 859-868. (doi:10.1111/j.1365-2265.2007.02825.x)
5. Colao A, Cappabianca P, Caron P, De Menis E, Farrall AJ, Gadelha MR, Hmissi A, Rees A, Reincke M, Safari M et al. Octreotide LAR vs. surgery in newly diagnosed patients with acromegaly: A randomized, open-label, multicentre study. Clinical Endocrinology 2009 70 757-768. (doi:10.1111/j.1365-2265. 2008.03441.x)
6. Fougner SL, Bollerslev J, Latif F, Hald JK, Lund T, Ramm-Pettersen J & Berg JP. Low levels of Raf kinase inhibitory protein in growth hormone-secreting pituitary adenomas correlate with poor response to octreotide treatment. Journal of Clinical Endocrinology and Metabolism 2008 93 1211-1216. (doi:10.1210/jc.2007-2272)
7. Fougner SL, Casar-Borota O, Heck A, Berg JP & Bollerslev J. Adenoma granulation pattern correlates to clinical variables and effect of somatostatin analogue treatment in a large series of patients with acromegaly. Clinical Endocrinology 2012 76 96-102. (doi:10.1111/j.1365-2265.2011.04163.x)
8. Gadelha MR, Kasuki L & Korbonits M. Novel pathway for somatostatin analogs in patients with acromegaly. Trends in Endocrinology and Metabolism 2013 24 238-246. (doi:10.1016/ j.tem.2012.11.007)
9. Colao A, Auriemma RS, Lombardi G & Pivonello R. Resistance to somatostatin analogs in acromegaly. Endocrine Reviews 2011 32 247-271. (doi:10.1210/er.2010-0002)
10. Fougner SL, Borota OC, Berg JP, Hald JK, Ramm-Pettersen J & Bollerslev J. The clinical response to somatostatin analogues in acromegaly correlates to the somatostatin receptor subtype 2a protein expression of the adenoma. Clinical Endocrinology 2008 68 458-465. (doi:10.1111/j.1365-2265.2007. 03065.x)
11. Heck A, Ringstad G, Fougner SL, Casar-Borota O, Nome T, Ramm-Pettersen J & Bollerslev J. Intensity of pituitary adenoma on T2-weighted magnetic resonance imaging predicts the response to octreotide treatment in newly diagnosed acromegaly. Clinical Endocrinology 20127772-78. (doi:10.1111/j.1365- 2265.2011.04286.x)
12. Bhayana S, Booth GL, Asa SL, Kovacs K & Ezzat S. The implication of somatotroph adenoma phenotype to somatostatin analog responsiveness in acromegaly. Journal of Clinical Endocrinology and Metabolism 2005 90 6290-6295. (doi:10.1210/jc.2005-0998)
13. Taboada GF, Luque RM, Neto LV, Machado Ede O, Sbaffi BC, Domingues RC, Marcondes JB, Chimelli LM, Fontes R, Niemeyer P et al. Quantitative analysis of somatostatin receptor subtypes (1-5) gene expression levels in somatotropinomas and correlation to in vivo hormonal and tumor volume responses to treatment with octreotide LAR. European Journal of Endocrinology 2008 158 295-303. (doi:10.1530/EJE-07-0562)
14. Neto LV, Machado Ede O, Luque RM, Taboada GF, Marcondes JB, Chimelli LM, Quintella LP, Niemeyer P Jr, de Carvalho DP & Gadelha MR. Expression analysis of dopamine receptor subtypes in normal human pituitaries, nonfunctioning pituitary adenomas and somatotropinomas, and the association between dopamine and somatostatin receptors with clinical response to octreotide-LAR in acromegaly. Journal of Clinical Endocrinology and Metabolism 2009 94 1931-1937. (doi:10.1210/jc.2008-1826)
15. Taboada GF, Luque RM, Bastos W, Guimaraes RF, Marcondes JB, Chimelli LM, Fontes R, Mata PJ, Filho PN, Carvalho DP et al. Quantitative analysis of somatostatin receptor subtype (SSTR1-5) gene expression levels in somatotropinomas and non-functioning pituitary adenomas. European Journal of Endocrinology 2007 156 65-74. (doi:10.1530/eje.1.02313)
16. Ferone D, de HerderWW, Pivonello R, Kros JM, van Koetsveld PM, de Jong T, Minuto F, Colao A, Lamberts SW & Hofland LJ. Correlation of in vitro and in vivo somatotropic adenoma responsiveness to somatostatin analogs and dopamine agonists with immunohistochemical evaluation of somatostatin and dopamine receptors and electron microscopy. Journal of Clinical Endocrinology and Metabolism 2008 93 1412-1417. (doi:10.1210/ jc.2007-1358)
17. Wildemberg LE, Vieira Neto L, Costa DF, Nasciutti LE, Takiya CM, Alves LM & Gadelha MR. Validation of immunohistochemistry for somatostatin receptor subtype 2A in human somatotropinomas: Comparison between quantitative real time RT-PCR and immunohistochemistry. Journal of Endocrinological Investigation 2012 35 580-584. (doi:10.3275/7906)
18. Gatto F, Feelders RA, van der Pas R, Kros JM, Waaijers M, Sprij-Mooij D, Neggers SJ, van der Lelij AJ, Minuto F, Lamberts SW et al. Immunoreactivity score using an anti-sst2A receptor monoclonal antibody strongly predicts the biochemical response to adjuvant treatment with somatostatin analogs in acromegaly. Journal of Clinical Endocrinology and Metabolism 2013 98 E66-E71. (doi:10.1210/jc.2012-2609)
19. Salehi F, Agur A, Scheithauer BW, Kovacs K, Lloyd RV & Cusimano M. Ki-67 in pituitary neoplasms: A review-part I. Neurosurgery 2009 65 429-437. (doi:10.1227/01.NEU.0000 349930.66434.82)
20. Fusco A, Zatelli MC, Bianchi A, Cimino V, Tilaro L, Veltri F, Angelini F, Lauriola L, Vellone V, Doglietto F et al. Prognostic significance of the Ki-67 labeling index in growth hormonesecreting pituitary adenomas. Journal of Clinical Endocrinology and Metabolism 2008 93 2746-2750. (doi:10.1210/jc.2008- 0126)
21. Giustina A, Chanson P, Bronstein MD, Klibanski A, Lamberts S, Casanueva FF, Trainer P, Ghigo E, Ho K & Melmed S. A consensus on criteria for cure of acromegaly. Journal of Clinical Endocrinology and Metabolism 2010 95 3141-3148. (doi:10.1210/jc.2009-2670)
22. Lundin P & Pedersen F. Volume of pituitary macroadenomas: Assessment by MRI. Journal of Computer Assisted Tomography 1992 16 519-528. (doi:10.1097/00004728-199207000-00004)
23. Knosp E, Steiner E, Kitz K & Matula C. Pituitary adenomas with invasion of the cavernous sinus space: A magnetic resonance imaging classification compared with surgical findings. Neurosurgery 1993 33 610-617. (doi:10.1227/00006123-199310000-00008)
24. Kasuki Jomori de Pinho L, Vieira Neto L, ArmondiWildemberg LE, Gasparetto EL, Marcondes J, de Almeida Nunes B, Takiya CM & Gadelha MR. Low aryl hydrocarbon receptor-interacting protein expression is a better marker of invasiveness in somatotropinomas than Ki-67 and p53. Neuroendocrinology 2011 94 39-48. (doi:10.1159/000322787)
25. Wildemberg LE, Vieira Neto L, Costa DF, Nasciuti LE, Takiya CM, Alves LM, Rebora A, Minuto F, Ferone D & Gadelha MR. Low somatostatin receptor subtype 2, but not dopamine receptor subtype 2, expression predicts the lack of biochemical response of somatotropinomas to treatment with somatostatin analogs. Journal of Endocrinological Investigation 2013 36 38-43. (doi:10.3275/8305)
26. Leontiou CA, Gueorguiev M, van der Spuy J, Quinton R, Lolli F, Hassan S, Chahal HS, Igreja SC, Jordan S, Rowe J et al. The role of the aryl hydrocarbon receptor-interacting protein gene in familial and sporadic pituitary adenomas. Journal of Clinical Endocrinology and Metabolism 2008 93 2390-2401. (doi:10.1210/jc.2007-2611)
27. Lloyd RV, Kovacs K, Young WF Jr, Farrel WE, Asa SL, Trouillas J, Kontogeorgos G, Sano T, Scheithauer BW & Horvath E. Pituitary tumours: Introduction. In WHO Classification of Tumours. Pathology and Genetics. Tumours of Endocrine Organs, pp 10-13. Eds RA DeLellis, RV Lloyd, PU Heitz & C Eng, Lyon: IARC Press, 2004.
28. Obari A, Sano T, Ohyama K, Kudo E, Qian ZR, Yoneda A, Rayhan N, Mustafizur Rahman M & Yamada S. Clinicopathological features of growth hormone-producing pituitary adenomas: Difference among various types defined by cytokeratin distribution pattern including a transitional form. Endocrine Pathology 2008 19 82-91. (doi:10.1007/s12022-008-9029-z)
29. Freda PU, Katznelson L, van der Lely AJ, Reyes CM, Zhao S & Rabinowitz D. Long-acting somatostatin analog therapy of acromegaly: A meta-analysis. Journal of Clinical Endocrinology and Metabolism 2005 90 4465-4473. (doi:10.1210/jc.2005-0260)
30. Murray RD & Melmed S. A critical analysis of clinically available somatostatin analog formulations for therapy of acromegaly. Journal of Clinical Endocrinology and Metabolism 2008 93 2957-2968. (doi:10.1210/jc.2008-0027)
31. Cozzi R, Attanasio R, Montini M, Pagani G, Lasio G, Lodrini S, Barausse M, Albizzi M, Dallabonzana D & Pedroncelli AM. Four-year treatment with octreotide-long-acting repeatable in 110 acromegalic patients: Predictive value of short-term results? Journal of Clinical Endocrinology and Metabolism 2003 88 3090-3098. (doi:10.1210/jc.2003-030110)
32. Jallad RS, Musolino NR, Salgado LR & Bronstein MD. Treatment of acromegaly with octreotide-LAR: Extensive experience in a Brazilian institution. Clinical Endocrinology 2005 63 168-175. (doi:10.1111/j.1365-2265.2005.02317.x)
33. Nakashima M, Takano K & Matsuno A. Analyses of factors influencing the acute effect of octreotide in growth hormonesecreting adenomas. Endocrine Journal 2009 56 295-304. (doi:10.1507/endocrj.K08E-305)
34. Kasuki L, Vieira Neto L, Wildemberg LE, Colli LM, de Castro M, Takiya CM & Gadelha MR. AIP expression in sporadic somatotropinomas is a predictor of the response to octreotide LAR therapy independent of SSTR2 expression. Endocrine-Related Cancer 2012 19 L25-L29. (doi:10.1530/ERC-12-0020)
35. Chahal HS, Trivellin G, Leontiou CA, Alband N, Fowkes RC, Tahir A, Igreja SC, Chapple JP, Jordan S, Lupp A et al. Somatostatin analogs modulate AIP in somatotroph adenomas: The role of the ZAC1 pathway. Journal of Clinical Endocrinology and Metabolism 2012 97 E1411-E1420. (doi:10.1210/jc.2012-1111)